Skip to content
Peptigraph home
Shop Peptides50% off*

Is retatrutide for diabetes?

Not yet as a medicine: retatrutide is described as under investigation for obesity, type 2 diabetes and related conditions, so any diabetes use so far is within trials.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Not yet as a medicine: retatrutide is described as under investigation for obesity, type 2 diabetes and related conditions, so any diabetes use so far is within trials.[1]

What the type 2 diabetes trials measured

In the phase 2 diabetes trial, HbA1c fell 2.02% in the 12 mg escalation group against 1.41% on 1.5 mg dulaglutide and 0.01% on placebo.[2]

In the phase 3 trial of adults whose diabetes was inadequately controlled by diet and exercise, HbA1c fell 1.94% on 12 mg against 0.81% on placebo.[3]

A review of phase 2 data says 27% of participants with type 2 diabetes reached normoglycemia, defined as an HbA1c below 5.7%.[4]

In people with obesity and type 2 diabetes, the phase 3 trial found weight fell 18.8% on 12 mg at week 80 against 5.1% on placebo.[1]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can women take retatrutide?Can you build muscle on retatrutide?

More on Retatrutide

BenefitsClaimed benefits next to what published studies measured.Retatrutide overview

Sources

  1. 1Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026
  2. 2Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet (London, England) · 2023PMID 37385280Accessed 2 Oct 2026
  3. 3Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 42250575Accessed 2 Oct 2026
  4. 4Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.Cardiology in review · 2026PMID 42108533Accessed 2 Oct 2026

Found an error? Report a correction.